Cowen and Company

Cowen and Company

Cowen and Company offers comprehensive investment banking services, including equity, equity-linked and debt financings, and mergers and acquisitions advisory services. In addition, the firm offers its clients access to world-class research, institutional sales and trading services and a comprehensive suite of prime brokerage services.


Time filter

Source Type

ALISO VIEJO, CA--(Marketwired - May 12, 2017) - BrainChip Holdings Ltd. ( : BRN) ("BrainChip" or "the Company"), a leading developer of software and hardware accelerated solutions for Advanced Artificial Intelligence and Machine Learning applications, is pleased to announce that Robert Beachler, Senior Vice President of Marketing and Business Development, will be participating in the Cowen and Company 45th Annual Technology, Media & Telecom Conference. The investor conference will be held May 31 through June 1, 2017, at the Lotte New York Palace in New York City. The Cowen TMT Conference is one of the premiere venues for technology companies and investors to meet and exchange ideas. Mr. Beachler will be speaking as part of the Artificial Intelligence: Streamlining Machine Intelligence to the End-User panel, scheduled for Thursday, June 1, 1:00-1:55 PM EDT. Cowen and Company analysts Derek Wood, Managing Director - SaaS & Data/Analytics Software Analyst, and Bryan Bergin, Vice President - IT & Business Services Analyst, will moderate the panel. Louis DiNardo, BrainChip's President and CEO, commented, "We are pleased to be included in this year's event and introduce the Company to investors. The TMT Conference is a major industry event that attracts top institutional investors as well as leading companies in the technology market. The panel discussion, which focuses on Artificial Intelligence, is intended to address the challenges faced by end-users. BrainChip's approach to quickly building models and autonomously extracting features and patterns without the extensive training required by Deep Learning methods eliminates a great deal of friction associated with deploying AI solutions in real-world applications." Mr. Beachler will be available to meet one-on-one with investors during the conference. Interested investors should contact their Cowen sales representative to secure a meeting time. About Cowen and Company Cowen and Company offers comprehensive investment banking services, including equity, equity-linked and debt financings, and mergers and acquisitions advisory services. In addition, the firm offers its clients access to world-class research, institutional sales and trading services and a comprehensive suite of prime brokerage services. About BrainChip Holdings Ltd. ( : BRN) BrainChip Holdings Ltd. is a leading provider of software and hardware accelerated solutions for Advanced Artificial Intelligence and Machine Learning applications. The Company has developed a revolutionary new Spiking Neural Adaptive Processor (SNAP) technology that can learn autonomously, evolve and associate information just like the human brain. The technology, which is proprietary, is fast, completely digital, and consumes very low power. The Company provides software and hardware solutions that address the high-performance requirements in Civil Surveillance, Gaming, Facial Recognition and Visual Inspection systems. www.brainchipinc.com.


News Article | May 25, 2017
Site: globenewswire.com

SOUTH SAN FRANCISCO, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $22.50 per share, for gross proceeds of $112.5 million before deducting underwriting discounts and commissions and offering expenses payable by Achaogen. In addition, Achaogen has granted the underwriters of the offering a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.  All of the shares are being offered by Achaogen. Achaogen currently expects to use the net proceeds from this offering to fund its ongoing development and preparation for potential commercialization of plazomicin, including funding for plazomicin manufacturing, research and development of its C-Scape program, and any remaining proceeds for working capital and general corporate purposes, including research and development of its other product candidates. The offering is expected to close on or about May 31, 2017, subject to satisfaction of customary closing conditions. Leerink Partners, Cowen and Stifel are acting as joint book-running managers for the offering. Guggenheim Securities and Wedbush PacGrow are acting as joint lead co-managers for the offering. A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on May 8, 2017. This offering is being made solely by means of such registration statement, including a prospectus supplement and the accompanying prospectus forming a part of the registration statement. Copies of the prospectus supplement and the accompanying prospectus related to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at syndicate@leerink.com, or by phone at 800-808-7525, ext. 6132; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by calling (631) 274-2806, or by fax (631) 254-7140; Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, Attn: Syndicate, by phone at 415-364-2720 or by email at syndprospectus@stifel.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The U.S. Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections (BSI) caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. All product candidates are investigational only and have not been approved for commercialization. This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Achaogen’s statements regarding the completion, timing and use of proceeds of the proposed public offering. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Achaogen’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, market conditions and the satisfaction of closing conditions related to the proposed public offering, the uncertainties inherent in the drug development and commercialization process, including regulatory requirements, the timing and results of Achaogen’s regulatory filings, Achaogen’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of plazomicin, Achaogen’s reliance on third-party contract manufacturing organizations to manufacture and supply its product candidates and certain raw materials used in the production thereof, Achaogen’s dependence on its President and Chief Executive Officer and risks and uncertainties related to the acceptance of government funding for certain of Achaogen’s programs. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Achaogen’s business in general, see Achaogen’s preliminary prospectus supplement filed with the SEC on May 23, 2017, including the documents incorporated by reference therein, which includes Achaogen’s current and future reports filed with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 and its Annual Report on Form 10-K for the fiscal year ended December 31, 2016.


News Article | May 25, 2017
Site: globenewswire.com

TROY, Mich., May 25, 2017 (GLOBE NEWSWIRE) -- Syntel, Inc. (Nasdaq:SYNT), a leading global provider of integrated information technology and knowledge process services, today announced that the Company will present at the following upcoming investor conference: Cowen and Company 45th Annual Technology Media & Telecom Conference Date: Thursday, June 1, 2017 Presentation: 8:00 AM (Eastern) Location: New York, NY Presenter: Zaineb Bokhari, VP Finance Live webcast available on Syntel's website at http://investor.syntelinc.com/events.cfm Syntel (Nasdaq:SYNT) is a leading global provider of integrated information technology and knowledge process services. Syntel helps global enterprises evolve the core by leveraging automation, scaled agile and cloud platforms to build efficient application development and management, testing and infrastructure solutions. Syntel’s digital services enable companies to engage customers, discover new insights through analytics, and create a more connected enterprise through the internet of things. Syntel’s "Customer for Life" philosophy builds collaborative partnerships and creates long-term client value by investing in IP, solutions and industry-focused delivery teams with deep domain knowledge. To learn more, visit us at: www.syntelinc.com This news release may include forward-looking statements, including those with respect to the future level of business for Syntel, Inc. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements as a result of certain risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 or from other factors not currently anticipated.


News Article | May 27, 2017
Site: www.fooddive.com

Costco on Thursday reported that third quarter fiscal 2017 net sales rose 8% year over year to $28.22 billion, while net sales for the first 36 weeks year-to-date rose 6% from the same period last year to $84.82 billion, according to a company press release. Same-store sales in the quarter, excluding gas and foreign currency fluctuations, rose 5% overall and 5% in the U.S., 3% in Canada and 6% elsewhere internationally. For the first 36 weeks of the year, same-store sales rose 3% overall. E-commerce sales rose 11% in the quarter, while revenue from membership fees rose to $644 million from $ 618 million last year. Q3 net income was $700 million, or $1.59 per diluted share, compared to $545 million, or $1.24 per diluted share. That topped FactSet analyst expectations cited by The Street for $1.31 per share. Year to date, net income rose to $1.76 billion, or $3.99 per diluted share, compared to $1.57 billion, or $3.56 per diluted share, last year. Amazon is challenging warehouse clubs, but doesn’t seem to be denting Costco’s numbers much, as the warehouse retailer continues to focus on its brick-and-mortar operations. The percentage of U.S. households that pay for Amazon Prime but hold no other club membership has grown from 7.1% in 2013 to 16.2% in 2016, while the percentage belonging to just Costco fell to 9.8% from 14.9%, and households belonging to Sam’s Club fell to 9.7% from 16.9%, according to research from Cowen and Co. released last year. Costco is comfortable with its "offensive" e-commerce strategy, CFO Richard Galanti told analysts Thursday, according to a transcript from Seeking Alpha, adding that the retailer isn’t “really worried about what others are doing.” “[N]ot to be arrogant or cavalier about it, but we feel good about what we are doing, we have got great brick-and-mortar comps, we are doing things offensively in our view, not defensively, and we have got a lot of things going on the online side,” Galanti said. While partnering with Instacart, Google Express and other third-parties for online orders, the retailer keeps its focus mostly on driving members into stores and enhancing its “treasure hunt” atmosphere, he said. He acknowledged that competition from Amazon and other players, including newcomer no-frills grocery-and-sundries retailer Lidl, will indeed present a challenge. But, he said, other retailers are likely to lose more market share than Costco. “[I]t’s traditional food retail that is getting hit more than us,” he said. “We have to keep driving our members into our warehouse and we do that with of course great prices and great items, certainly fresh foods, certainly gas stations… which brings them into parking lot, if you will, and certainly the loyalty program … all those have helped us, and then the treasure hunt,” he said. “[W]e are asked a lot about [Lidl] coming into the East Coast, they are going to take share, but they are going to take share from everybody else a lot more than they can take share from us. So we haven’t really seen a big change like people buying less at Costco because of other formats out there.”


News Article | May 24, 2017
Site: globenewswire.com

BOSTON, May 24, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 2,200,000 shares of its common stock at a price to the public of $20.50 per share. Albireo’s gross proceeds from this offering are expected to be approximately $45.1 million, before deducting underwriting discounts and commissions and estimated offering expenses.  In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 330,000 shares of common stock on the same terms and conditions.  All of the shares in the offering are being sold by Albireo. The offering is expected to close on or about May 30, 2017, subject to customary closing conditions. Cowen and William Blair are acting as joint book-running managers and representatives of the underwriters for the offering. Needham & Company and Wedbush PacGrow are acting as co-managers. The offering will be made only by means of a written prospectus and related prospectus supplement forming part of a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) on December 22, 2016 and declared effective by the SEC on January 10, 2017. The preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC on May 23, 2017. The final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available at the SEC’s website located at www.sec.gov, copies of which may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by telephone at 631-274-2806, and from William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, or by telephone at 1-800-621-0687 or email at prospectus@williamblair.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Albireo Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 3 product candidates and one Phase 2 product candidate. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden.


News Article | May 24, 2017
Site: www.businesswire.com

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $11.50 per share. The gross proceeds from the offering are expected to be $80.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by GlycoMimetics. The offering is expected to close on or about May 30, 2017, subject to customary closing conditions. Jefferies LLC and Cowen are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. is acting as lead manager for the offering. GlycoMimetics has granted to the underwriters a 30-day option to purchase up to 1,050,000 additional shares of common stock at the public offering price, less the underwriting discount. GlycoMimetics intends to use the net proceeds of the offering to complete its ongoing Phase 1/2 clinical trial of GMI-1271 in patients with acute myeloid leukemia (AML) and its ongoing Phase 1 clinical trial of GMI-1271 in patients with multiple myeloma (MM), to initiate and conduct a portion of a potential Phase 3 pivotal clinical trial of GMI-1271 in patients with relapsed/refractory AML, to fund the research and development of its preclinical pipeline, including drug discovery, and for working capital and other general corporate purposes. A shelf registration statement relating to this offering was filed with the Securities and Exchange Commission (SEC) on March 17, 2015 and declared effective by the SEC on March 24, 2015. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at Prospectus_Department@Jefferies.com, or by phone at (877) 821-7388; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by phone at (631) 274-2806. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, Maryland in the BioHealth Capital Region. Any statements in this press release about future expectations, plans and prospects for GlycoMimetics, Inc., including statements about the Company’s anticipated public offering, anticipated use of proceeds and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the completion of ongoing clinical trials and the initiation of future clinical trials and such other factors as are set forth in the risk factors detailed in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2017 and the preliminary prospectus supplement filed with the SEC on May 22, 2017 under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.


News Article | May 24, 2017
Site: globenewswire.com

LITTLE ROCK, Ark., May 24, 2017 (GLOBE NEWSWIRE) -- Tony Thomas, president and chief executive officer of Windstream (NASDAQ:WIN), will speak at 1 p.m. CDT on Wednesday, May 31 at the Cowen and Company 45th Annual Technology, Media & Telecom Conference in New York City. A live webcast of the event will be available at www.windstream.com/investors. The webcast will be archived on the website for 90 days. Windstream Holdings, Inc. (NASDAQ:WIN), a FORTUNE 500 company, is a leading provider of advanced network communications and technology solutions for consumers, small businesses, enterprise organizations and carrier partners across the U.S. Windstream offers bundled services, including broadband, security solutions, voice and digital TV to consumers. The company also provides data, cloud solutions, unified communications and managed services to business and enterprise clients. The company supplies core transport solutions on a local and long-haul fiber-optic network spanning approximately 147,000 miles. Additional information is available at windstream.com. Please visit our newsroom at news.windstream.com or follow us on Twitter at @Windstream.


SUNNYVALE, CA--(Marketwired - May 23, 2017) - eGain ( : EGAN), the leading provider of cloud customer engagement solutions, today announced that Ashu Roy, CEO, will present at the Cowen and Company 45th Annual Technology, Media & Telecom Conference on Thursday, June 1, 2017 at 2:45 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investor Relations section of eGain's website at www.egain.com. A replay of the webcast will be made available for 90 days following the event. To arrange a one-on-one meeting with eGain management, please contact either your Cowen salesperson, or the MKR Group, eGain's investor relations firm, at egan@mkr-group.com. About eGain eGain customer engagement solutions power digital transformation for leading brands. Our top-rated cloud applications for social, mobile, web, and contact centers help clients deliver connected customer journeys in an omnichannel world. To find out more about eGain Corporation, visit http://www.egain.com. eGain, the eGain logo, and all other eGain product names and slogans are trademarks or registered trademarks of eGain Corp. in the United States and/or other countries. All other company names and products mentioned in this release may be trademarks or registered trademarks of the respective companies.


News Article | May 23, 2017
Site: globenewswire.com

BOSTON, May 23, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced an underwritten public offering of its common stock. In connection with the offering, Albireo intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering.  All of the shares in the offering will be sold by Albireo. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Cowen and William Blair are acting as joint book-running managers and representatives of the underwriters for the offering. Needham & Company and Wedbush PacGrow are acting as co-managers. The offering will be made only by means of a written prospectus and related prospectus supplement forming part of a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) on December 22, 2016 and declared effective by the SEC on January 10, 2017. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available at the SEC’s website located at www.sec.gov, copies of which may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by telephone at 631-274-2806, and from William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, or by telephone at 1-800-621-0687 or email at prospectus@williamblair.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 3 product candidates and one Phase 2 product candidate. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden.


News Article | May 23, 2017
Site: globenewswire.com

RESEARCH TRIANGLE PARK, N.C., May 23, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the closing of its initial public offering of 7,781,564 shares of common stock at a public offering price of $15.00 per share, including 781,564 shares sold pursuant to the partial exercise of the underwriters’ option to purchase additional shares. G1 Therapeutics received approximately $108.6 million in proceeds from the offering, net of underwriting discounts and commissions, but before estimated offering expenses. The shares began trading on The NASDAQ Global Select Market on May 17, 2017 under the ticker symbol “GTHX.” J.P. Morgan Securities LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Needham & Company, LLC and Wedbush PacGrow acted as co-managers for the offering. A registration statement relating to these securities was filed with and has been declared effective by the Securities and Exchange Commission on May 16, 2017. The offering was made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by telephone at (866) 803-9204, or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806 or by faxing (631) 254-7140. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is based in Research Triangle Park, NC.

Loading Cowen and Company collaborators
Loading Cowen and Company collaborators